AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Axsome Therapeutics, Inc.
Video analysis: AXSM
All videosNo video analysis for this stock yet. Request one from our team.
News: AXSM
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments. Viking Therapeutics remains a clinical-stage player with significant potential in the high-demand obesity and metabolic disease markets.
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m.
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.
